Dow Chemical’s DOW fully-owned subsidiary, Dow AgroSciences LLC and Arcadia Biosciences, Inc. has collaborated to develop and commercialize a breakthrough improved wheat quality trait in North America. The partnership will capitalize on Arcadia’s leading non-GM Tilling trait development platform along with Dow AgroSciences’ enabling technology platforms, high-quality elite germplasm and global commercial channels.Per the agreement, both companies will further develop and commercialize an improved wheat quality trait which has completed initial field trials and is advancing to next-stage trials. Dow AgroSciences will introgress Arcadia’s trait into its proprietary elite germplasm lines and manage all aspects associated with the commercialization of the traits. Dow has underperformed the industry it belongs to over the last three months. The company’s shares have moved up around 2.8% over this period, compared with roughly 4.1% gain recorded by the industry. Dow is witnessing improved global economic activity with strong momentum in manufacturing, investment and trade. While strength of the consumer is driving expansion in the U.S., improvement in Europe is expected to remain on a steady track. The company is also seeing signs of stabilization in Latin America, especially in the agriculture market. Dow also believes that it is well positioned to capture demand in consumer-led markets. The company is expected to gain from its focus on consumer-led markets and its strategic investments in the U.S. Gulf Coast and the Middle East. Dow should also benefit from its productivity management actions and cost synergies associated with Dow Corning Silicones business. The planned merger with DuPont DD is also expected to create significant synergies.Dow Chemical Company (The) Price and Consensus Dow Chemical Company (The) Price and Consensus | Dow Chemical Company (The) QuoteDow Chemical currently carries a Zacks Rank #3 (Hold).Stocks to ConsiderSome better-ranked companies in the chemical space include Arkema S.A. ARKAY and Kronos Worldwide KRO. Both the stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.Arkema has an expected long-term earnings growth of 12.8%.Kronos Worldwide has an expected long-term earnings growth of 5%.More Stock News: Tech Opportunity Worth $386 Billion in 2017From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future. Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report E.I. du Pont de Nemours and Company (DD): Free Stock Analysis Report Dow Chemical Company (The) (DOW): Free Stock Analysis Report Kronos Worldwide Inc (KRO): Free Stock Analysis Report Arkema SA (ARKAY): Free Stock Analysis Report To read this article on Zacks.com click here.